KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:待检查 入排置信度 0.98

INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.

Danny Rischin, Aaron R Hansen, Ezra E W Cohen, Makoto Tahara, Kevin J Harrington, Robert I Haddad, Lisa Licitra, Hisham Mehanna, Robert L Ferris, Piotr Koralewski, Konstantin Penkov, Michael Schenker, David R Spigel, Amaury Daste, Min Hee Hong, Ye Guo, Michael J Chisamore, Michael L Washburn, Amy Phillips-Jones, John Russell, Sumita Roy-Ghanta, Catherine Ellis, Marc Ballas, Christophe Le Tourneau

Clin Cancer Res 32(6) 1087-1099

PMID41427951
PMCIDPMC13012248
DOI10.1158/1078-0432.CCR-25-1197
发表日期2025-12-22
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
AI 判定该论文不进入自动 KM 提取:The study is a combined Phase II/III trial with an adaptive design, and it was stopped early based on interim analysis, meaning it did not complete the Phase III portion as intended.
摘要

摘要

PURPOSE: Feladilimab, an inducible T-cell costimulatory receptor agonist, demonstrated clinical activity in combination with pembrolizumab in a phase I head and neck squamous cell carcinoma (HNSCC) expansion cohort, prompting further evaluation in patients in this setting. PATIENTS AND METHODS: INDUCE-3 (NCT04128696) was a randomized, double-blind, phase II/III study in patients with first-line PD-L1-positive recurrent and/or metastatic HNSCC. A 2-in-1 adaptive design was implemented, with an option to expand the phase II study into a phase III confirmatory study. Patients were randomized 1:1 to receive feladilimab plus pembrolizumab or placebo plus pembrolizumab, with up to 35 cycles of treatment for approximately 2 years. Primary endpoints were overall survival (OS) and investigator-assessed progression-free survival (PFS). RESULTS: The study enrolled 315 patients. Following the review of unblinded interim data in 140 patients, an Independent Data Monitoring Committee recommended stopping patient accrual based on prespecified criteria. Existing patients discontinued feladilimab or placebo. Pembrolizumab treatment continued until prespecified stopping criteria were met. This study demonstrated no evidence of an effect in favor of feladilimab plus pembrolizumab, with an adjusted HR of 1.51 for OS and 1.40 for PFS (median OS: 44.1 weeks [95% confidence interval (CI), 35.9-not applicable]; median PFS: 10.1 weeks [95% CI, 9.1-15]) versus placebo plus pembrolizumab [median OS: not reached; median PFS: 16 weeks (95% CI, 14.3-26.1)]. The incidence of treatment-related adverse events was higher in the placebo group. CONCLUSIONS: This analysis does not support the combination of feladilimab plus pembrolizumab due to a lack of superiority over placebo plus pembrolizumab.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。